Dyrenium

"The US Food and Drug Administration (FDA) has approved an expanded indication for onabotulinum toxin A (Botox, Actavis) for the treatment of adults with upper limb spasticity, according to a company news release.

Dyrenium

OVERDOSE

In the event of overdosage, it can be theorized that electrolyte imbalance
would be the major concern, with particular attention to possible hyperkalemia.
Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances
and weakness. It is conceivable that some hypotension could occur. As with an
overdose of any drug, immediate evacuation of the stomach should be induced
through emesis and gastriclavage. Careful evaluation of the electrolyte pattern
and fluid balance should be made. There is no specific antidote.

Reversible acute renal failure following ingestion of 50 tablets of a product containing a combination of 50 mg triamterene and 25 mg hydrochlorothiazide has been reported.

The oral LD50 in mice is 380 mg/kg. The amount of drug in a single dose ordinarily associated with symptoms of overdose or likely to be life-threatening is not known.

Although triamterene is 67% protein bound, there may be some benefit to dialysis in cases of overdosage.

CONTRAINDICATIONS

Dyrenium (triamterene) should not be used in patients with pre-existing elevated serumpotassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with Dyrenium (triamterene) .

Dyrenium (triamterene) should not be given to patients receiving other potassium-sparing
agents, such as spironolactone, amiloride hydrochloride, or other formulations
containing triamterene. Two deaths have been reported in patients receiving
concomitant spironolactone and Dyrenium (triamterene) or Dyazide®. Although dosage recommendations
were exceeded in one case and in the other serum electrolytes were not properly
monitored, these two drugs should not be given concomitantly.

Last reviewed on RxList: 5/28/2008
This monograph has been modified to include the generic and brand name in many instances.